StreetInsider.com News Articles

Satellos drug candidate SAT-3247 receives WHO nonproprietary name

Wed, 09 Sep 2026 07:00:16 -0400

Satellos Bioscience (Nasdaq: MSLE, TSX: MSCL) announced that the World Health Organization has assigned the International Nonproprietary Name "forazapadin" to its oral small molecule drug candidate previously known as SAT-3247, which is being developed to treat degenerative muscle diseases.

Forazapadin targets AAK1, a protein the company has identified as capable of supporting muscle repair and regeneration. The drug is being evaluated in two Phase 2 studies in patients with Duchenne muscular dystrophy (DMD): the BASECAMP study, a randomized, placebo-controlled trial in pediatric participants, and the TRAILHEAD study, an open-label trial in adult participants.

Satellos said it expects to complete enrollment in the

Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247

Wed, 09 Sep 2026 07:00:00 -0400

TORONTO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience (Nasdaq: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle diseases, today announced the assignment of the International Nonproprietary Name (INN) “forazapadin” for the Company's orally administered, small molecule drug candidate designed to restore muscle regeneration that was previously known as SAT-3247.

“As we continue to execute our clinical development strategies, this naming designation reflects the maturity of the program and supports its future development as we plan for regulatory submission and commercialization in Duchenne muscular dystrophy,” said Frank Gleeson,

Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247

Wed, 09 Sep 2026 07:00:00 -0400

Satellos to Participate in Upcoming Investor Conferences

Tue, 01 Sep 2026 07:00:00 -0400

TORONTO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle diseases, today announced that management will participate in the following investor conferences in September.

2026 Cantor Global Healthcare Conference
Date: Wednesday, September 9, 2026
Presentation: 3:55 p.m. EDT
Location: New York, NY
Webcast: here

H.C. Wainwright 28^th Annual Global Investment Conference
Date: Wednesday, September 16, 2026
Fireside chat: 9 a.m. EDT
Location: New York, NY
Webcast: here

Members

Satellos to Participate in Upcoming Investor Conferences

Tue, 01 Sep 2026 07:00:00 -0400

2026 Cantor Global Healthcare Conference
Date: Wednesday, September 9, 2026
Presentation: 3:55 p.m. EDT
Location: New York, NY
Webcast: here

H.C. Wainwright 28^th Annual Global Investment Conference
Date: Wednesday, September 16, 2026
Fireside chat: 9 a.m. EDT
Location: New York, NY
Webcast: here

Members

Form 6-K Satellos Bioscience Inc. For: Aug 14

Fri, 14 Aug 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260814/26931653.html

Form 6-K Satellos Bioscience Inc. For: Aug 14

Fri, 14 Aug 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260814/26931653.html

Form SUPPL Satellos Bioscience Inc.

Fri, 14 Aug 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260814/26931158.html

Form SUPPL Satellos Bioscience Inc.

Fri, 14 Aug 2026 16:26:00 -0400

si-local-file:///var/storage/secattach/20260814/26931158.html

Form 6-K Satellos Bioscience Inc. For: Jun 30

Thu, 13 Aug 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260813/26922560.html

Form 6-K Satellos Bioscience Inc. For: Jun 30

Thu, 13 Aug 2026 17:03:00 -0400

si-local-file:///var/storage/secattach/20260813/26922560.html

Form F-X Satellos Bioscience Inc. Filed by: Satellos Bioscience Inc.

Tue, 11 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260811/26906023.html

Form F-X Satellos Bioscience Inc. Filed by: Satellos Bioscience Inc.

Tue, 11 Aug 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20260811/26906023.html

Form F-10 Satellos Bioscience Inc.

Tue, 11 Aug 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260811/26905471.html

Form F-10 Satellos Bioscience Inc.

Tue, 11 Aug 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260811/26905471.html

Satellos Bioscience Inc. (MSLE) PT Raised to $18 at H.C. Wainwright

Thu, 09 Jul 2026 06:52:51 -0400

(Updated - July 9, 2026 6:52 AM EDT)

H.C. Wainwright analyst Arthur He raised the price target on Satellos Bioscience Inc. (NASDAQ: MSLE) to $18.00 (from $11.00) while maintaining a Buy rating.

The analyst commented: "On July 8, Satellos reported 6-month interim data from the Phase 2 TRAILHEAD study of SAT-3247 in adults with Duchenne muscular dystrophy (DMD). Recall, the TRAILHEAD study enrolled the four adults (aged 21–28) who previously completed 28-day treatment with 60 mg SAT-3247 in the Phase 1b CL-101 study and restarted treatment for up to 12 months. We believe the two most important data points from the 6-month

Satellos Bioscience Inc. (MSLE) PT Raised to $18 at H.C. Wainwright

Thu, 09 Jul 2026 06:52:51 -0400

(Updated - July 9, 2026 6:52 AM EDT)

H.C. Wainwright analyst Arthur He raised the price target on Satellos Bioscience Inc. (NASDAQ: MSLE) to $18.00 (from $11.00) while maintaining a Buy rating.

Satellos reports 6-month interim data for DMD drug candidate SAT-3247

Wed, 08 Jul 2026 06:34:10 -0400

Satellos Bioscience Inc. (NASDAQ: MSLE) released six-month interim data from its TRAILHEAD clinical study evaluating SAT-3247, an investigational drug candidate for Duchenne muscular dystrophy (DMD), according to a company statement.

The interim results were drawn from four adult participants aged 21 to 28 who had previously completed the Phase 1a/b CL-101 study. Over an average of 186 days of drug exposure, all four participants showed a decline in muscle fat fraction as measured by MRI, with a mean improvement of 3.7%, moving from 49.7% at baseline to 46.0% at month six.

All four participants also showed an increase in upper limb maximum

Satellos reports 6-month interim data for DMD drug candidate SAT-3247

Wed, 08 Jul 2026 06:34:10 -0400

All four participants also showed an increase in upper limb maximum

Form 6-K Satellos Bioscience Inc. For: Jul 08

Wed, 08 Jul 2026 06:30:00 -0400

si-local-file:///var/storage/secattach/20260708/26743919.html

Form 6-K Satellos Bioscience Inc. For: Jul 08

Wed, 08 Jul 2026 06:30:00 -0400

si-local-file:///var/storage/secattach/20260708/26743919.html

Form 6-K Satellos Bioscience Inc. For: Jul 08

Wed, 08 Jul 2026 06:30:00 -0400

si-local-file:///var/storage/secattach/20260708/26743919.html

Form 6-K Satellos Bioscience Inc. For: Jun 29

Mon, 29 Jun 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260629/26701870.html

Form 6-K Satellos Bioscience Inc. For: Jun 29

Mon, 29 Jun 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260629/26701870.html

Form 6-K Satellos Bioscience Inc. For: Jun 29

Mon, 29 Jun 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260629/26701870.html